PRMT5 inhibitor

Prelude Therapeutics raises $60M in Series B round for solid tumor, blood cancer drug

The company is developing a PRMT5 inhibitor, currently in a Phase I study for lymphomas, myeloid malignancies and solid tumors.

By Alaric DeArment

Price Transparency is the New North in the PBM World

In this episode hear how improving benefit verification, prior authorizations, and patient affordability with smart integrations and real-time eligibility can streamline healthcare workflows.

By MedCity News and Abarca

Discover the Most Effective Aquatic Therapy Programs in Chicago Suburbs

Incorporating aquatic therapy can enhance patient outcomes and shorten recovery times for health care professionals. In the Chicago suburbs, the demand for such programs is rising.

By FYZICAL Therapy & Balance Centers

The Top EAP Companies for Mental Health Support

Employee assistance programs have become essential tools for organizations aiming to address mental health challenges, reduce burnout and foster healthier workplaces.

By AllOne Health